PetPace, the provider of an innovative IoT collar for remote real-time monitoring and analysis of pet vital signs and activity, today released the findings of a new medical case study. The cardiac case study, available for download here, documents in detail how the PetPace collar detected signs of imminent Congestive Heart Failure in a dog.
The patient, Lucas, is a 10-year-old male Beagle who suffers from Chronic Valvular Heart Disease (CVHD). He is treated regularly with Benazepril and wears a PetPace smart collar to monitor his condition. Recently, the PetPace collar documented deterioration in Lucas’ condition, which culminated in Congestive Heart Failure.
PetPace detected gradual changes in several parameters which were indicative of Lucas’ impending condition. To start, both minimum pulse rate and minimum respiratory rate showed gradual, incremental increases over several weeks, as seen in the accompanied charts.
Heart Rate Variability (HRV), an established indicator of various heart diseases, also showed a clear decrease during the same period of time (low HRV is indicative of poor cardiac health).
Following diagnosis of congestive heart failure, Lucas was treated first with a diuretic (Furosemide), and then another drug (Vetmedin®). Throughout the treatment, PetPace provided valuable monitoring and feedback regarding treatment efficacy. For example, as seen in the HRV graph, treatment with furosemide brought quick but short-lived improvement. The addition of a second drug, Vetmedin® (Pimobendan), produced a gradual but sustained improvement.
The PetPace collar is unique in its ability to assist in the remote medical management of pets with heart disease. It provides early detection of trends preceding clinical deterioration, long before the pet shows overt symptoms. Moreover, it allows for close monitoring of the effect of certain drugs, potentially facilitating better clinical management.
“Clinicians can now use innovative wearable technology to remotely assess the condition of cardiac patients, detect worrisome trends and closely follow the effect of their chosen course of treatment,” said Dr. Asaf Dagan, DVM, Diplomate ABVP (Canine and Feline practice), and PetPace’s Chief Veterinarian. “The impact of such capabilities on longevity and quality of life for patients with CVHD, and other conditions as well, may be tremendous,” he continued.
“The trends of data changes provided by the PetPace collar during hemodynamic deterioration and in response to pharmacotherapy carry an immense potential,” noted Dr. Dan Ohad, DVM, PhD, Diplomate ACVIM and ECVIM (Cardiology) from Koret School of Veterinary Medicine, of the Hebrew University of Jerusalem, Israel. “For both a timely diagnosis, far before the patient experiences life-threatening complications, and for timely therapeutic decision-making – PetPace can enable prompt rectification of developments before they ‘snowball’ and potentially get out of control,” he concluded.
PetPace was founded in 2012 to bring peace of mind to pet owners and prevent unnecessary pain and suffering for dogs and cats through improved pet health and quality of life. PetPace specializes in the remote monitoring of pet vital signs by utilizing advanced analytical methods and alerting models. The company’s low power, wireless collar is fitted with an array of sensors that report abnormal vital signs within established physiological and behavioral parameters. Once an abnormal sign or behavior is detected, a sophisticated cloud-based analytical engine evaluates the signs and if needed, sends an immediate alert regarding any suspected condition. This allows the owner or the vet to take preemptive action to protect the pet’s health. For more information about PetPace real-time pet health monitoring, visit http://PetPace.com.